OncoMed Pharmaceuticals IPO Research Information

OncoMed Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on OncoMed Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
OncoMed Pharmaceuticals	OMED - NASDAQ	$14.00-$16.00	$17.00	$17.00	4.8 million	7/18/2013
Underwriter(s): Jefferies, Leerink Swann
Co-Manager(s): Piper Jaffray, BMO Capital Markets
Industry: Health Care
Filing(s): Filed 2012-05-11

OncoMed Pharmaceuticals Quote & Chart - Click for current quote - OMED

About OncoMed Pharmaceuticals (adapted from OncoMed Pharmaceuticals prospectus):
They are a clinical development-stage biopharmaceutical company focused on discovering and developing first-in-class monoclonal antibody therapeutics targeting cancer stem cells, or CSCs.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "OMED" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.